Proteins of *Bartonella bacilliformis*: Candidates for Vaccine Development

Cesar Henriquez-Camacho, 1 Palmira Ventosilla, 2 Michael F. Minnick, 3 Joaquim Ruiz, 4 and Ciro Maguiná 2

1Hospital Universitario Fundacion Alcorcon, Calle Budapest 1, 28922 Madrid, Spain
2Instituto de Medicina Tropical "Alexander von Humboldt", Universidad Peruana Cayetano Heredia, Lima 31, Peru
3Division of Biological Sciences, University of Montana, Missoula, MT 59812, USA
4ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clinic, Universitat de Barcelona, 08036 Barcelona, Spain

Correspondence should be addressed to Cesar Henriquez-Camacho; cajhenriquez@fhalconcon.es

Received 31 May 2015; Revised 2 August 2015; Accepted 6 August 2015

Copyright © 2015 Cesar Henriquez-Camacho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Bartonella bacilliformis* is the etiologic agent of Carrión’s disease or Oroya fever. *B. bacilliformis* infection represents an interesting model of human host specificity. The notable differences in clinical presentations of Carrión’s disease suggest complex adaptations by the bacterium to the human host, with the overall objectives of persistence, maintenance of a reservoir state for vectorial transmission, and immune evasion. These events include a multitude of biochemical and genetic mechanisms involving both bacterial and host proteins. This review focuses on proteins involved in interactions between *B. bacilliformis* and the human host. Some of them (e.g., flagellin, Brps, IalB, FtsZ, Hbp/Pap31, and other outer membrane proteins) are potential protein antigen candidates for a synthetic vaccine.

1. Introduction

*Bartonella bacilliformis* is a member of the alpha-2 subgroup of Proteobacteria and is the etiologic agent of Carrión’s disease or Oroya fever in humans. Bartonellosis has been historically described in Peru, Ecuador, and Colombia [1, 2], with Peru considered the most important endemic area in the world. This disease often, but not always, presents in a biphasic manner. The primary, life-threatening acute phase is characterized by a septic state worsened by a severe hemolytic anemia (bacteria invade the erythrocytes which are destroyed by the spleen) [3]. This phase, known as Oroya fever, has a high fatality rate (up to 88%) if not treated and is more common in children [4]. Fever, pallor, general malaise, myalgia, headache, jaundice, and hepato/splenomegaly are the main symptoms of Oroya fever [1]. Some patients develop, as a consequence of the septic state, a transient immunosuppression that results in the onset of opportunistic infections such as toxoplasmosis, tuberculosis, salmonellosis, shigellosis, histoplasmosis, malaria, and pneumocystosis [1, 5, 6]. In the secondary chronic phase, known as verruga peruana (Peruvian wart), the bacteria invade the endothelial cells producing wart-like hemangiomatous lesions of the skin and mucous membranes 4 to 8 weeks after the onset of Oroya fever. The duration of the eruptive phase is 3 to 6 months. Lesions are classified as miliary (small reddish papules < 3 mm in diameter), mular (nodular tumors > 5 mm), and diffuse subdermal nodules [7]. Inhabitants, especially schoolchildren, in endemic regions often develop the eruptive phase as the sole manifestation of the disease [8]. Humans are the only known natural reservoir for *B. bacilliformis* [7, 9]. *B. bacilliformis* is believed to be transmitted to humans by bites of phlebotomine sand flies living in the high mountain valleys of the Andes [10].

Since *B. bacilliformis* was first described in 1905 by Alberto Barton; numerous research studies have been reported, including clinical and experimental studies. In the last 25 years, arguably the most important studies have been conducted to explain the physiopathology of the disease.
The notable differences in clinical presentations during a *B. bacilliformis* infection suggest a complex adaptation to the human host with the objectives of persistence, maintenance of a reservoir state for vector-based transmission, and immune evasion. The bacterium-host relationship evokes a multitude of biochemical and genetic mechanisms involving both bacterial and host proteins.

This review focuses on proteins involved in *B. bacilliformis* interactions with the human host. We hypothesize that certain proteins would be ideal protein antigen candidates to be included in a chemically synthesized vaccine to block *B. bacilliformis* interactions with host cells (see Figure 1).

**Flagellin.** *B. bacilliformis* cells are highly motile by lophotrichous flagella, appendages consisting of ~42 kDa flagellin protein subunits that are resistant to protease or trypsin treatment [11]. *B. bacilliformis* was reported to possess 1 to 10 polar flagella 3 to 10 μm in length [11]. In addition to blood flow within the circulatory system, flagella provide the bacterium with a high degree of mobility and may serve to propel the pathogen during its search for erythrocytes [12].

Bacterial motility seems to be required for internalization, since entry of nonmotile *B. bacilliformis* was not observed in the experiments of Mernaugh and Ihler [13].

Antiserum to flagella significantly reduced *B. bacilliformis* association with red cells as compared to controls [11], and there was poor adherence of nonmotile variants and flagellin-minus (bald) mutants [14, 15]. These data suggest that flagella may possess adhesive qualities and/or they increase bacteria-host cell interactions [11]. In view of the significant decrease in erythrocyte infection due to antiflagellin antibodies, this protein is a promising antigen for use in a potential subunit vaccine.

**Brps.** *Bartonella* species invade a variety of eukaryotic cells by employing trimeric autotransporter adhesion proteins (TAAs) [16]. The TAAs all use a type V secretion pathway and consist of a passenger domain and a beta domain used to deliver the passenger component out of the cell via the outer membrane. *B. bacilliformis* possesses three *brp* genes encoding potential *Bartonella* repeat proteins (Brps) [17]. *B. bacilliformis* Brp proteins share common domains and structural features with the TAAs. While the biological role of *B. bacilliformis* Brp proteins has not yet been investigated, they may be involved in similar biological processes as the TAA proteins of *B. henselae* and *B. quintana*, including autoagglutination, adhesion to host cells and extracellular matrix proteins (fibronectin and collagens), inhibition of phagocytosis, and induction of a proangiogenic response in host cells [10]. Immune-mediated inhibition of these hypothetical functions could possibly confer protection against the pathogen.

**ialB.** The invasion-associated locus B (IalB) protein (see Figure 2) was originally discovered by screening a *B. bacilliformis* genomic library for erythrocyte-invasive strains of host *E. coli* [18]. IalB has a significant effect on enhancing *B. bacilliformis*' erythrocyte invasion. It is possible that environmental changes during passage of the bacterium from sand fly to humans (e.g., changes in temperature, iron availability, and pH) have an effect on ialB gene expression [19]. In other research, IalB protein levels were correlated with changes in ialB mRNA and changes of temperature/pH of the growth media. The greatest amount of ialB was present in *B. bacilliformis* that had been acid-shocked (pH 5), grown at 20°C, or temperature downshifted to 20°C from 30°C. As with ialB mRNA levels, IalB protein amounts in *B. bacilliformis* decreased in response to basic pH (pH 8.0) or a temperature upshift to 37°C [20].

Presumably, *B. bacilliformis* undergoes a temperature shift from 37°C to 20°C when it is ingested by a sand fly, as the blood meal in the insect cools to ambient temperature.
Concurrent with this temperature downshift, bacterial *ialB* expression would presumably be upregulated for erythrocyte invasion following transfer to another human host when the insect subsequently feeds. A change of the pH also occurs in the sand fly midgut (pH increases slightly to pH 7.4), where *ialB* expression would presumably be upregulated.

When bacteria pass from the sand fly vector to a human host, the event would be signalled by a rapid upshift in temperature to 37°C and an increase in pH to 7.4. The *ialB* gene has been included in MLST schemes to study clonal and evolutionary relatedness of *B. bacilliformis* strains [23].

### 2. Miscellaneous Outer Membrane Proteins

Several *B. bacilliformis* outer membrane proteins have been identified by a variety of means. Minnick identified 14 proteins ranging from 11.2 to 75.3 kDa. Three of these proteins (31.5, 42, and 45 kDa) were prominent immunoprecipitants when they were exposed to rabbit hyperimmune serum [24]. Iwaki-Egawa and Ihler identified six *B. bacilliformis* proteins that mediate bacterial interactions with erythrocytes (100, 92, 84, 46, 37, and 12 kDa) [25].

A 43 kDa immunogenic lipoprotein of *B. bacilliformis* was identified through screening of a genomic DNA lambda library. The protein is a homolog to the LppB proteins of *Haemophilus spp.* and the NlpD protein of *E. coli* and was thus designated LppB [24]. The LppB lipoprotein is likely to use the same biosynthetic pathway as other bacterial lipoproteins. The protein's prominent immunogenicity was demonstrated using five convalescent sera from patients with Oroya fever or verruga peruana [26].

Buckles and McGinnis Hill demonstrated that *B. bacilliformis* was able to bind to several human erythrocyte proteins, including α and β subunits of spectrin, band 3 protein, glycophorin A, and glycophorin B [27]. Band 3 is a major transmembrane glycoprotein of the erythrocyte membrane, and it may be one of the possible erythrocyte receptors of *B. bacilliformis* [27]. In addition, band 3 has been suggested to be involved Plasmodium invasion of erythrocytes [28, 29].

### 3. Hemin-Binding Proteins (Hbp’s)

The *B. bacilliformis* hemin-binding proteins (Hbp’s) are homologs of the bacteriophage-associated, Pap31, protein of *Bartonella henselae* [30] and the five hemin-binding proteins of *B. quintana* [31, 32]. *B. bacilliformis* possesses three, tandem *hbp*-encoding genes in its chromosome. In addition to serving as a receptor for hemin and associating with the phage coat, data from work with *B. henselae* suggest that these proteins may also serve as adhesins for fibronectin, heparin, and host cells such as endothelial cells [33]. The Hbp (Pap31) proteins are highly expressed antigens in growing cultures of *B. bacilliformis* and are immunologically dominant, making them ideal antigens for use in enzyme-linked immunosorbent assays (ELISAs) and in immunoblots. In fact, use of this single protein antigen permits the use of ELISA, Western blot methods, or rapid lateral flow assay for the diagnosis of a *B. bacilliformis* infection [34]. To what extent *B. bacilliformis* Hbp’s are immunoreactive in humans is unknown. However, the HbPE homolog of *B. quintana* is a commonly recognized antigen in sera from trench fever patients [35]. This observation suggests that one or more *B. bacilliformis* Hbp’s may also be seroreactive in humans and thus useful subunit vaccine candidates.

### 4. Conclusions

*B. bacilliformis* infection represents an interesting model of human host specificity by a bacterium. While we now know more about the biology of the bacterium and the pathogenesis of Carrión’s disease, we still lack adequate knowledge to select...
specific protein candidates to generate a subunit vaccine formulation. Studies regarding comparative genomics and proteomics are sorely lacking, especially considering the significant impact that bartonellosis outbreaks represent for the affected populations in South America. Carrión's disease is an emerging infectious disease that is not amenable to eradication with antibiotics or pesticides. Thus, the most effective intervention strategy to improve public health will be the development of a vaccine. Advances in _B. bacilliformis_ genomics and proteomics hold the promise a rational vaccine design in the near future [36].

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**References**

[1] C. Maguíña and E. Gotuzzo, “BARTONELLOSIS: new and old,” Infectious Disease Clinics of North America, vol. 14, no. 1, pp. 1–22, 2000.

[2] B. Alexander, “A review of bartonellosis in Ecuador and Colombia,” American Journal of Tropical Medicine and Hygiene, vol. 52, no. 4, pp. 354–359, 1995.

[3] C. Henriquez, J. C. Hinojosa, P. Ventosilla et al., “Report of an unusual case of persistent bacteremia by Bartonella bacilliformis in a splenectomized patient,” American Journal of Tropical Medicine and Hygiene, vol. 71, no. 1, pp. 53–55, 2004.

[4] E. Huarcaya, C. Maguíña, R. Torres, J. Rupay, and L. Fuentes, “Bartonellosis (Carrión’s Disease) in the pediatric population of Peru: an overview and update,” Brazilian Journal of Infectious Diseases, vol. 8, no. 5, pp. 331–339, 2004.

[5] G. C. Gray, A. A. Johnson, S. A. Thornton et al., “An epidemic of Oroya fever in the Peruvian Andes,” American Journal of Tropical Medicine and Hygiene, vol. 42, no. 3, pp. 215–221, 1990.

[6] C. Maguín Vargas, C. Ugarte-Gil, P. Breña Chávez et al., “Actualización de la enfermedad de Carrión,” Revista Médica Herediana, vol. 19, no. 1, pp. 36–41, 2008.

[7] C. Maguín, H. Guerra, and P. Ventosilla, “Bartonellosis,” Clinics in Dermatology, vol. 27, no. 3, pp. 271–280, 2009.

[8] M. Kosek, R. Lavarello, R. H. Gilman et al., “Natural history of infection with _Bartonella bacilliformis_ in a nonendemic population,” Journal of Infectious Diseases, vol. 182, no. 3, pp. 865–872, 2000.

[9] J. Knobloch, “Analysis and preparation of _Bartonella bacilliformis_ antigens,” American Journal of Tropical Medicine and Hygiene, vol. 39, no. 2, pp. 173–178, 1988.

[10] M. F. Minnick, B. E. Anderson, A. Lima, J. M. Battisti, P. G. Lawyer, and R. J. Birtles, “Oroya fever and verruga peruana: bartonelloses unique to South America,” PLoS Neglected Tropical Diseases, vol. 8, no. 7, Article ID e2919, 2014.

[11] D. C. Scherer, I. Deburon-Connors, and M. E. Minnick, “Characterization of _Bartonella bacilliformis_ flagella and effect of antiflagellin antibodies on invasion of human erythrocytes,” Infection and Immunity, vol. 61, no. 12, pp. 4962–4971, 1993.

[12] M. F. Minnick, S. J. Mitchell, and S. J. McAllister, “Cell entry and the pathogenesis of _Bartonella_ infections,” Trends in Microbiology, vol. 4, no. 9, pp. 343–347, 1996.

[13] G. Mernaugh and G. M. Ihler, “Deformation factor: an extracellular protein synthesized by _Bartonella bacilliformis_ that deforms erythrocyte membranes,” Infection and Immunity, vol. 60, no. 3, pp. 937–943, 1992.

[14] L. A. Benson, S. Kar, G. McLaughlin, and G. M. Ihler, “Entry of _Bartonella bacilliformis_ into erythrocytes,” Infection and Immunity, vol. 54, no. 2, pp. 347–353, 1986.

[15] J. M. Battisti and M. F. Minnick, “Development of a system for genetic manipulation of _Bartonella bacilliformis_,” Applied and Environmental Microbiology, vol. 65, no. 8, pp. 3441–3448, 1999.

[16] T. Riess, S. G. E. Andersson, A. Lupas et al., “ _Bartonella_ adhesin a mediates a proangiogenic host cell response,” The Journal of Experimental Medicine, vol. 200, no. 10, pp. 1267–1278, 2004.

[17] P. O. Kaiser, T. Riess, F. O’Rourke, D. Linke, and V. A. J. Kemp, “ _Bartonella sp.: throwing light on uncommon human infections_,” International Journal of Medical Microbiology, vol. 301, no. 1, pp. 7–15, 2011.

[18] S. J. Mitchell and M. F. Minnick, “Characterization of a two-gene locus from _Bartonella bacilliformis_ associated with the ability to invade human erythrocytes,” Infection and Immunity, vol. 63, no. 4, pp. 1552–1562, 1995.

[19] S. A. Coleman and M. F. Minnick, “Establishing a direct role for the _Bartonella bacilliformis_ invasion-associated locus B (ialB) protein in human erythrocyte parasitism,” Infection and Immunity, vol. 69, no. 7, pp. 4373–4381, 2001.

[20] S. A. Coleman and M. F. Minnick, “Differentiation expression of the invasion-associated locus B (ialB) gene of _Bartonella bacilliformis_ in response to environmental cues,” Microbial Pathogenesis, vol. 34, no. 4, pp. 179–186, 2003.

[21] M. R. Chenoweth, C. E. Greene, D. C. Krause, and F. C. Gherardini, “Predominant outer membrane antigens of _Balgonella henselae_,” Infection and Immunity, vol. 72, no. 6, pp. 3097–3105, 2004.

[22] I. Padmalayam, B. Anderson, M. Kron, T. Kelly, and B. Baumstark, “The 75-kilodalton antigen of _Bartonella bacilliformis_ is a structural homolog of the cell division protein FtsZ,” Journal of Bacteriology, vol. 179, no. 14, pp. 4545–4552, 1997.

[23] G. L. Chaloner, P. Ventosilla, R. J. Birtles, and M. Picardeau, “Multi-focus sequence analysis reveals profound genetic diversity among isolates of the human pathogen _Bartonella bacilliformis_,” PLoS Neglected Tropical Diseases, vol. 5, no. 7, p. e1248, 2011.

[24] M. F. Minnick, “Identification of outer membrane proteins of _Bartonella bacilliformis_,” Infection and Immunity, vol. 62, no. 6, pp. 2644–2648, 1994.

[25] S. Iwaki-Egawa and G. M. Ihler, “Comparison of the abilities of proteins from _Bartonella bacilliformis_ and _Bartonella henselae_ to deform red cell membranes and to bind to red cell ghost proteins,” FEMS Microbiology Letters, vol. 157, no. 1, pp. 207–217, 1997.

[26] I. Padmalayam, T. Kelly, B. Baumstark, and R. Massung, “Molecular cloning, sequencing, expression, and characterization of an immunogenic 43-kilodalton lipoprotein of _Bartonella bacilliformis_ that has homology to NlpD/LppB,” Infection and Immunity, vol. 68, no. 9, pp. 4972–4979, 2000.

[27] E. L. Buckles and E. McGinnis Hill, “Interaction of _Bartonella bacilliformis_ with human erythrocyte membrane proteins,” Microbial Pathogenesis, vol. 29, no. 3, pp. 165–174, 2000.

[28] E. Roggswiller, M. E. M. Bé Toule, T. Blisnick, and C. B. Breton, “A role for erythrocyte band 3 degradation by the parasite gp76 serine protease in the formation of the parasitophorous vacuole
during invasion of erythrocytes by *Plasmodium falciparum*; Molecular and Biochemical Parasitology, vol. 82, no. 1, pp. 13–24, 1996.

[29] H. K. Deng, D. Le Rhun, E. Le Naour, S. Bonnet, and M. Vayssier-Taussat, “Identification of Bartonella Trw host-specific receptor on erythrocytes,” *PLoS ONE*, vol. 7, no. 7, Article ID e41447, 2012.

[30] T. J. Bowers, D. Sweger, D. Jue, and B. Anderson, “Isolation, sequencing and expression of the gene encoding a major protein from the bacteriophage associated with *Bartonella henselae*,” *Gene*, vol. 206, no. 1, pp. 49–52, 1998.

[31] M. F. Minnick, K. N. Sappington, L. S. Smitherman, S. G. E. Andersson, O. Karlberg, and J. A. Carroll, “Five-member gene family of *Bartonella quintana*,” *Infection and Immunity*, vol. 71, no. 2, pp. 814–821, 2003.

[32] J. A. Carroll, S. A. Coleman, L. S. Smitherman, and M. F. Minnick, “Hemin-binding surface protein from *Bartonella quintana*,” *Infection and Immunity*, vol. 68, no. 12, pp. 6750–6757, 2000.

[33] S. M. Dabo, A. W. Confer, B. E. Anderson, and S. Gupta, “*Bartonella henselae* Pap31, an extracellular matrix adhesin, binds the fibronectin repeat III13 module,” *Infection and Immunity*, vol. 74, no. 5, pp. 2513–2521, 2006.

[34] A. Taye, H. Chen, K. Duncan et al., “Production of recombinant protein Pap31 and its application for the diagnosis of *Bartonella bacilliformis* infection,” *Annals of the New York Academy of Sciences*, vol. 1063, pp. 280–285, 2005.

[35] J. K. Boonjakuakul, H. L. Gerns, Y.-T. Chen et al., “Proteomic and immunoblot analyses of *Bartonella quintana* total membrane proteins identify antigens recognized by sera from infected patients,” *Infection and Immunity*, vol. 75, no. 5, pp. 2548–2561, 2007.

[36] D. L. Doolan, S. H. Apte, and C. Proietti, “Genome-based vaccine design: the promise for malaria and other infectious diseases,” *International Journal for Parasitology*, vol. 44, no. 12, pp. 901–913, 2014.